De Bari B, Lestrade L, Souquet P-J, Pacheco Y, Geriniere L, Guibert B, Mornex F
Département de radiothérapie-oncologie, centre hospitalier Lyon-Sud, chemin du Grand-Revoyet, Pierre-Bénite, France.
Cancer Radiother. 2012 Apr;16(2):107-14. doi: 10.1016/j.canrad.2011.10.009. Epub 2012 Feb 14.
Superior sulcus non-small cell lung cancer represents less than 5% of all lung cancers and is a challenge for the physicians because of clinical presentation, treatments related toxicities and poor prognosis. The aim of this preliminary retrospective report is to present outcomes of patients affected by a superior sulcus non-small cell lung cancer, treated by high dose radiotherapy (>60 Gy) with or with our chemotherapy.
All adult inoperable or unresectable patients (≥18 years) with a clinical and radiological diagnosis of superior sulcus non-small cell lung cancer treated in our department by radiotherapy with or without chemotherapy were retrospectively analysed. Primary endpoint was the local control. Overall survival, metastasis free survival and toxicity rates were also analysed and reported.
From January 1999 to June 2009, 12 patients were treated by exclusive high-dose radiochemotherapy. Median age was 53 years (range: 33-64 years); mean follow-up time was 20 months (range: 2-75 months). Mean local control, overall survival and metastasis free survival were 20.2, 22 and 20 months, respectively. At the time of this analysis, seven patients died of cancer and three of them presented only a metastatic disease progression. One patient died of acute cardiac failure 36 months after the end of radiochemotherapy and was disease free. Treatment was well tolerated and any acute and/or late G3-4 toxicity was recorded (NCI-CTC v 3.0 score).
This analysis confirms the interest of exclusive high-dose radiochemotherapy in treating inoperable superior sulcus non-small cell lung cancer patients, in achieving good local control and overall survival rates.
肺上沟非小细胞肺癌占所有肺癌的比例不到5%,因其临床表现、治疗相关毒性和预后不良,给医生带来了挑战。本初步回顾性报告的目的是介绍接受高剂量放疗(>60 Gy)联合或不联合化疗的肺上沟非小细胞肺癌患者的治疗结果。
对在我院接受放疗联合或不联合化疗的所有成年不可手术或无法切除(≥18岁)且临床和影像学诊断为肺上沟非小细胞肺癌的患者进行回顾性分析。主要终点是局部控制。还分析并报告了总生存期、无转移生存期和毒性率。
1999年1月至2009年6月,12例患者接受了单纯高剂量放化疗。中位年龄为53岁(范围:33 - 64岁);平均随访时间为20个月(范围:2 - 75个月)。平均局部控制、总生存期和无转移生存期分别为20.2个月、22个月和20个月。在本次分析时,7例患者死于癌症,其中3例仅出现转移性疾病进展。1例患者在放化疗结束36个月后死于急性心力衰竭,且无疾病复发。治疗耐受性良好,未记录到任何急性和/或晚期3 - 4级毒性(NCI - CTC v 3.0评分)。
该分析证实了单纯高剂量放化疗在治疗不可手术的肺上沟非小细胞肺癌患者、实现良好的局部控制率和总生存率方面的有效性。